PHVS Pharvaris
- 22.620
- -0.060-0.26%
- 22.620
- 0.0000.00%
Pharvaris News
Damo: Maintaining the Pharvaris (PHVS.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $34.00 to $34.00.
Pharvaris Analyst Ratings
Morgan Stanley Maintains Overweight on Pharvaris, Maintains $34 Price Target
Damo: Maintaining the Pharvaris (PHVS.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $35.00 to $34.00.
Pharvaris Analyst Ratings
Pharvaris Earns Buy Rating as Deucrictibant Shows Promising Progress in HAE Treatment
Buy Rating Affirmed for Pharvaris on Strong HAE Drug Potential and Solid Financials
Wedbush: Reiterates the Pharvaris (PHVS.US) rating and adjusted from superior to superior market rating, with a target price of $35.00.
Pharvaris Analyst Ratings
Wedbush Reiterates Outperform on Pharvaris, Maintains $35 Price Target
Wedbush Reaffirms Their Buy Rating on Pharvaris (PHVS)
Buy Rating Affirmed for Pharvaris on Strong Clinical Progress and Financial Stability
Optimistic Buy Rating for Pharvaris on Advancement in Phase 3 HAE Treatment Trial
Pharvaris Analyst Ratings
Wedbush Reiterates Outperform on Pharvaris, Maintains $35 Price Target
Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Alpine Immune Sciences (ALPN) and IGM Biosciences (IGMS)
Pharvaris Buy Rating Affirmed Amid Promising Phase 3 HAE Trial Prospects
Pharvaris Buy Rating Affirmed on Strong Phase 2 Data and Market Positioning for HAE Treatment
JMP Securities Reiterates Market Outperform on Pharvaris, Maintains $49 Price Target
Pharvaris Analyst Ratings
Analysis
Price Target
No Data
